- Why Work With NSF?
A core expertise of NSF Pharma Biotech is our ability to organize and execute small- to large-scale corporate-wide quality system remediation efforts. These can be proactive efforts, where companies recognize internally the need to enhance their existing systems, or they can be reactive, precipitated by an adverse regulatory action or inspection. Our team of consultants includes former industry leaders who have real-world insight into how companies operate and can implement practical solutions that are sustainable, efficient, compliant and scalable.
As FDA and other regulatory agencies focus more on compliance and enforcement actions, it is imperative that companies respond quickly and effectively to mitigate potential risks to production, reputation and the bottom line. Our consultants excel not only at identifying areas in need of remediation, but at efficiently developing and implementing sustainable remediation solutions to meet your company's specific immediate and long-term needs.
For more information about NSF Pharma Biotech services in quality systems and compliance in the U.S., email firstname.lastname@example.org or call +1 202.822.1850.
For more information about NSF Pharma Biotech services in quality systems and compliance in Europe, email email@example.com or call +44 1751 432 999.
Why Work With NSF?
Our remediation services are known and trusted throughout the pharmaceutical world. We don't provide you with an off-the-shelf solution that will take you years to turn into a sustainable solution; rather, we work with you to develop and implement a remediation solution that meets your needs and dovetails with your existing systems.
- 2 days ago
FDA Regulatory and Compliance News FDA’s Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee convened to discuss...
NSF International cordially invites you to join us at APIC 2015 Annual Conference When: June 27-29, 2015 Where: Nashville, TN...
- 2 weeks ago
FDA Regulatory and Compliance News FDA announced the approval of Bayer HealthCare Pharmaceuticals’ Avelox (moxifloxacin) to treat patients with pneumonic...
- Monday, June 1, 2015
- 8:30am - 4:00pm GMT
- Manchester, United Kingdom
- Tuesday, June 2, 2015
- 9:00am - 3:00pm GMT
- Manchester, UK, United Kingdom
- Thursday, June 4, 2015
- 8:30am - 3:00pm GMT
- York, United Kingdom
- Thursday, June 11, 2015
- 1:00pm - 2:00pm GMT
- Webinar, United Kingdom